Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Role of Subgingival Instrumentation in Oral Lichen Planus

NCT07381595 · tracked via the Priya Life Science India tracker
Phase
Not applicable
Started
2026-03-01
Last updated
2026-02-06

Condition(s) studied

Oral Lichen Planus

Investigational drug(s) / intervention(s)

subgingival instrumentation

subgingival instrumentation: Subgingival instrumentation like scaling and root planing of the recruited subject shall be done.

Study summary

The goal of this interventional study is to assess the clinical and histopathological changes in Oral Lichen Planus patients with gingival involvement pre and post subgingival instrumentation.

Objective- Primary objective: To observe and evaluate the clinical signs and symptoms in Oral Lichen Planus with gingival involvement. Secondary objective: To observe and evaluate the Cluster of Differentiation (CD) 4+ and 8+T lymphocytes in Oral Lichen Planus with gingival involvement.

Study group: 30 cases of Oral Lichen Planus with gingival involvement

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * Clinically and histopathologically confirmed cases of OLP. * OLP predominantly involving the gingiva. * Consent obtained. Exclusion criteria: * Cases which does not fulfil either clinical or histopathological criteria. * Unwilling to participate in the study. * Patients with recorded history of factors that might modify immune response (such as patient on corticosteroids or medically compromised patients or suffering from heart diseases). * Cases undergoing treatment of OLP within past 6 months. * Biopsies with inadequate or non-representative samples * Cases histopathologically diagnosed as Lichenoid Dysplasia or Oral Lichenoid Lesions. * Cases diagnosed with autoimmune disorders.

Primary outcome measure(s)

  • Change in clinical signs and symptoms in cases of oral lichen planus — At baseline and after end of treatment at 4 weeks
    Clinical signs and symptoms will be recorded using oral disease severity score criteria

Trial sites (1)

FacilityCityRegionStatus
Post Graduate Institute of Dental Sciences Rohtak Haryana
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07381595 on ClinicalTrials.gov ↗ ← All trials in India